{{Rsnum
|rsid=4823613
|Gene=PPARA
|Chromosome=22
|position=46202410
|Orientation=plus
|GMAF=0.287
|Gene_s=PPARA
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 55.8 | 33.6 | 10.6
| HCB | 62.5 | 31.6 | 5.9
| JPT | 67.9 | 30.4 | 1.8
| YRI | 32.0 | 51.0 | 17.0
| ASW | 43.9 | 42.1 | 14.0
| CHB | 62.5 | 31.6 | 5.9
| CHD | 55.6 | 36.1 | 8.3
| GIH | 69.3 | 26.7 | 4.0
| LWK | 25.5 | 57.3 | 17.3
| MEX | 58.6 | 32.8 | 8.6
| MKK | 39.7 | 51.3 | 9.0
| TSI | 39.6 | 52.5 | 7.9
| HapMapRevision=28
}}{{PMID Auto
|PMID=23252946
|Title=Associations between the genotypes and phenotype of CYP3A and the lipid response to simvastatin in Chinese patients with hypercholesterolemia
}}

{{PMID Auto
|PMID=24113216
|Title=Single-nucleotide polymorphisms in P450 oxidoreductase and peroxisome proliferator-activated receptor-α are associated with the development of new-onset diabetes after transplantation in kidney transplant recipients treated with tacrolimus
}}

{{PMID Auto
|PMID=24353446
|Title=Cytochrome P450 3A4*22, PPAR-α, and ARNT polymorphisms and clopidogrel response
|OA=1
}}

{{PMID Auto
|PMID=24921414
|Title=Impact of PPARA and POR polymorphisms on tacrolimus pharmacokinetics and new-onset diabetes in kidney transplant recipients
}}
{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}